Skip to main content

Table 2 NT-proBNP, inflammatory markers, osteoprotegerin and fetuin-A during treatment with vitamin D analogs

From: The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study

 

Period 1

Period 2

 

Alfacalcidol

Paricalcitol

Difference between groups

Alfacalcidol

Paricalcitol

Difference between groups

 

Week 6

Week 22

Increase

Week 6

Week 22

Increase

Week 28

Week 44

Increase

Week 28

Week 44

Increase

NT-proBNP (pmol/l) median (range)

417.8 (78-19048) N = 26

606.2 (90-63974)

187.7 (-888-44932)

485.4 (79-13543) N = 29

785.5 (39-7766)

300.1 (-12433-6124)*

-121.1 (95%CI -429.4 to 187.2)

763.8 (55-2769) N = 29

1005.0 (43-8519)

155.8 (-1917-7680)

497.1 (54-42379) N = 26

487.6 (45-53669)

-42.1 (-3262-11290)

-429.7 (95%CI -938.1 to 78.8)

Log NT-proBNP

2.74 (0.60) N = 26

6.63 (1.47)

3.89 (0.19)#

2.76 (0.57) N = 29

6.69 (1.22)

3.93 (0.17)#

0.04 (95%CI -0.54 to 0.47)

6.39 (1.07) N = 29

6.73 (1.21)

0.34 (0.19)

6.60 (1.53) N = 26

6.37 (1.49)

-0.22 (0.13)

-0.56 (95% CI -1.04 to -0.10)¤

hs-Crp (mg/l) median (range)

9.61 (0.3 -28.0) N = 24

6.58 (0.4-73.2)

-0.07 (-21-63)

7.23 (0.3-27.7) N = 29

5.30 (0.3-81.0)

-0.01 (-21-66)

-0.76 (95%CI -5.9 to 4.4)

7.52 (0.6-62.4) N = 29

5.25 (0.2-34.3)

-0.31 (-55-11)

6.96 (0.25-48.3) N = 24

5.46 (0.37-60.8)

-1.18 (-46- 58)

-0.85 (95%CI -4.7 to 3.0)

Log hs-Crp

1.86 (1.20) N = 24

1.80 (1.38)

-0.06 (0.21)

1.54 (1.31) N = 29

1.58 (1.54)

0.03 (0.21)

0.09 (95%CI -0.69 to 0.51)

1.70 (1.29) N = 29

1.38 (1.38)

-0.32 (0.19)

1.93 (1.26) N = 24

1.67 (1.08)

-0.27 (0.27)

0.05 (95%CI -0.60 to 0.71)

IL-6 (pg/ml)

6.99 (5.34) N = 21

7.05 (8.40)

0.06 (1.90)

5.56 (3.68) N = 24

8.34 (14.24)

2.79 (2.64)

-2.73 (95%CI -9.47 to 4.01)

6.59 (3.51) N = 21

5.66 (5.21)

-0.93 (0.75)

6.11 (3.91) N = 24

5.90 (3.53)

-0.21 (1.07)

0.72 (95%CI -1.87 to 3.29)

TNF-α (pg/ml)

6.63 (2.45) N = 23

7.76 (6.16)

1.13 (1.32)

7.05 (2.20) N = 26

6.85 (2.28)

-0.21 (0.44)

1.34 (95%CI -1.33 to 4.00)

6.59 (2.36) N = 26

7.18 (3.00)

0.53 (1.32)

6.42 (2.26) N = 23

7.04 (2.19)

-1.22 (2.16)

- 1.75 (95%CI -6.72 to 3.21)

Fetuin-A (μg/ml)

319.15 (76.41) N = 23

362.92 (77.77)

43.77 (14.07)#

330.81 (81.83) N = 26

340.75 (84.98)

9.93 (9.62)

32.84 (95%CI 0.21 to 67.47) ¤

331.29 (107.15) N = 26

318.94 (91.32)

-12.35 (18.39)

329.55 (81.00) N = 23

299.20 (74.95)

-30.35 (22.26)

-42.7 (95%CI -75.62 to 33.69)

Osteoprotegerin (pg/ml)

4461.77 (1905.1), N = 22

4878.00 (1954.20)

416.23 (178.52)#

4009.39 (1636.80) N = 26

4442.15 (2147.7)

432.77 (193.65)#

16.54 (95%CI -544.13 to 521.05)

4333.4 (1947.1) N = 26

4567.04 (2003.1)

233.64 (102.55)#

4982.68 (1988.9) N = 22

4911.09 (1874.4)

-71.59 (209.52)

305.23 (95%CI -757.83 to 147.36)

  1. Distribution of NT-proBNP and hs-Crp was skewed and analyses were done by Mann-Whitney two sample test and presented with Hodge-Lehman median (95% confidence interval).
  2. Logarithmic transformed NT-proBNP and hs-Crp and the remaining parameters were compared using an unpaired t-test and presented with the mean difference (95% confidence intervals).
  3. *: Wilcoxon signed rank test P<0.05; #: Two-sample paired t-test P < 0.05; ¤: Two-sample unpaired t-test, P < 0.05. Parameters are presented as mean (SD) and differences in mean (SEM) unless specified otherwise.
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us